Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

D. Radovanovic, Marco Mantero, Giuseppe Francesco Sferrazza Papa, Vincenzo Valenti, Stefano Aliberti, Fabio Di Marco, Pierachille Santus

Research output: Contribution to journalArticle

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a high disability and increasing mortality. Bronchodilators are the cornerstone of pharmacological treatment in COPD, while therapeutic optimization with an improvement in symptoms and compliance represent the actual goals. This has led to the development of devices that combine different classes of inhalatory drugs. Recently, a novel combination of the long acting antimuscarinic agent glycopyrronium bromide and the beta2-agonist formoterol fumarate has been developed in a metered dose inhaler delivery system. Areas covered: The present article will discuss the current unmet needs in pharmacological therapy of COPD, will then briefly cover the pharmacokinetic and pharmacodynamic characteristics of the formoterol/glycopyrronium fixed dose combination and present the novel delivery system based on engineered microparticles and the co-suspension technology. Finally, efficacy and safety results of phase I, II and III trials will be reviewed. Expert commentary: The novel combination therapy of formoterol/glycopyrronium is the first available as a metered dose inhaler and proved to have a good efficacy and safety profile compared to monocomponents and tiotropium. Although still limited, data from phase III trials provide good evidence to consider it a valid option in the pharmacological management of patients with COPD.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalExpert Review of Respiratory Medicine
DOIs
Publication statusPublished - 2016

Fingerprint

Glycopyrrolate
Chronic Obstructive Pulmonary Disease
Metered Dose Inhalers
Pharmacology
Safety
Muscarinic Antagonists
Bronchodilator Agents
Therapeutics
Compliance
Suspensions
Pharmacokinetics
Technology
Equipment and Supplies
Mortality
Formoterol Fumarate
Pharmaceutical Preparations

Keywords

  • bronchodilation
  • chronic obstructive pulmonary disease
  • fixed dose combination
  • Formoterol fumarate
  • glycopyrronium bromide
  • metered dose inhaler
  • porous particles

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Cite this

Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease. / Radovanovic, D.; Mantero, Marco; Sferrazza Papa, Giuseppe Francesco; Valenti, Vincenzo; Aliberti, Stefano; Di Marco, Fabio; Santus, Pierachille.

In: Expert Review of Respiratory Medicine, 2016, p. 1-11.

Research output: Contribution to journalArticle

Radovanovic, D. ; Mantero, Marco ; Sferrazza Papa, Giuseppe Francesco ; Valenti, Vincenzo ; Aliberti, Stefano ; Di Marco, Fabio ; Santus, Pierachille. / Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease. In: Expert Review of Respiratory Medicine. 2016 ; pp. 1-11.
@article{420a7c9f3bc1431e8ce20ad6feb27260,
title = "Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease",
abstract = "Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a high disability and increasing mortality. Bronchodilators are the cornerstone of pharmacological treatment in COPD, while therapeutic optimization with an improvement in symptoms and compliance represent the actual goals. This has led to the development of devices that combine different classes of inhalatory drugs. Recently, a novel combination of the long acting antimuscarinic agent glycopyrronium bromide and the beta2-agonist formoterol fumarate has been developed in a metered dose inhaler delivery system. Areas covered: The present article will discuss the current unmet needs in pharmacological therapy of COPD, will then briefly cover the pharmacokinetic and pharmacodynamic characteristics of the formoterol/glycopyrronium fixed dose combination and present the novel delivery system based on engineered microparticles and the co-suspension technology. Finally, efficacy and safety results of phase I, II and III trials will be reviewed. Expert commentary: The novel combination therapy of formoterol/glycopyrronium is the first available as a metered dose inhaler and proved to have a good efficacy and safety profile compared to monocomponents and tiotropium. Although still limited, data from phase III trials provide good evidence to consider it a valid option in the pharmacological management of patients with COPD.",
keywords = "bronchodilation, chronic obstructive pulmonary disease, fixed dose combination, Formoterol fumarate, glycopyrronium bromide, metered dose inhaler, porous particles",
author = "D. Radovanovic and Marco Mantero and {Sferrazza Papa}, {Giuseppe Francesco} and Vincenzo Valenti and Stefano Aliberti and {Di Marco}, Fabio and Pierachille Santus",
year = "2016",
doi = "10.1080/17476348.2016.1227247",
language = "English",
pages = "1--11",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

AU - Radovanovic, D.

AU - Mantero, Marco

AU - Sferrazza Papa, Giuseppe Francesco

AU - Valenti, Vincenzo

AU - Aliberti, Stefano

AU - Di Marco, Fabio

AU - Santus, Pierachille

PY - 2016

Y1 - 2016

N2 - Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a high disability and increasing mortality. Bronchodilators are the cornerstone of pharmacological treatment in COPD, while therapeutic optimization with an improvement in symptoms and compliance represent the actual goals. This has led to the development of devices that combine different classes of inhalatory drugs. Recently, a novel combination of the long acting antimuscarinic agent glycopyrronium bromide and the beta2-agonist formoterol fumarate has been developed in a metered dose inhaler delivery system. Areas covered: The present article will discuss the current unmet needs in pharmacological therapy of COPD, will then briefly cover the pharmacokinetic and pharmacodynamic characteristics of the formoterol/glycopyrronium fixed dose combination and present the novel delivery system based on engineered microparticles and the co-suspension technology. Finally, efficacy and safety results of phase I, II and III trials will be reviewed. Expert commentary: The novel combination therapy of formoterol/glycopyrronium is the first available as a metered dose inhaler and proved to have a good efficacy and safety profile compared to monocomponents and tiotropium. Although still limited, data from phase III trials provide good evidence to consider it a valid option in the pharmacological management of patients with COPD.

AB - Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a high disability and increasing mortality. Bronchodilators are the cornerstone of pharmacological treatment in COPD, while therapeutic optimization with an improvement in symptoms and compliance represent the actual goals. This has led to the development of devices that combine different classes of inhalatory drugs. Recently, a novel combination of the long acting antimuscarinic agent glycopyrronium bromide and the beta2-agonist formoterol fumarate has been developed in a metered dose inhaler delivery system. Areas covered: The present article will discuss the current unmet needs in pharmacological therapy of COPD, will then briefly cover the pharmacokinetic and pharmacodynamic characteristics of the formoterol/glycopyrronium fixed dose combination and present the novel delivery system based on engineered microparticles and the co-suspension technology. Finally, efficacy and safety results of phase I, II and III trials will be reviewed. Expert commentary: The novel combination therapy of formoterol/glycopyrronium is the first available as a metered dose inhaler and proved to have a good efficacy and safety profile compared to monocomponents and tiotropium. Although still limited, data from phase III trials provide good evidence to consider it a valid option in the pharmacological management of patients with COPD.

KW - bronchodilation

KW - chronic obstructive pulmonary disease

KW - fixed dose combination

KW - Formoterol fumarate

KW - glycopyrronium bromide

KW - metered dose inhaler

KW - porous particles

UR - http://www.scopus.com/inward/record.url?scp=84984690359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984690359&partnerID=8YFLogxK

U2 - 10.1080/17476348.2016.1227247

DO - 10.1080/17476348.2016.1227247

M3 - Article

SP - 1

EP - 11

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

ER -